Fig. 4From: Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling studyIFX clearance estimation and patient diagnosis. Estimated IFX clearance values stratified based on patient diagnosis are presented as a box and whisker plot and evaluated by unpaired analysis using the Wilcoxon rank-sum test and the resulting p-values are providedBack to article page